Savara Inc. (YB4P.F)
- Previous Close
2.9200 - Open
2.9000 - Bid 2.9000 x --
- Ask 3.0000 x --
- Day's Range
2.9000 - 2.9000 - 52 Week Range
2.1600 - 4.8800 - Volume
2,000 - Avg. Volume
45 - Market Cap (intraday)
502.303M - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania.
www.savarapharma.comRecent News: YB4P.F
View MorePerformance Overview: YB4P.F
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YB4P.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YB4P.F
View MoreValuation Measures
Market Cap
518.33M
Enterprise Value
368.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.42
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.78%
Return on Equity (ttm)
-61.50%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-95.88M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
196.78M
Total Debt/Equity (mrq)
15.66%
Levered Free Cash Flow (ttm)
-51.5M